The Molecular Pathogenesis Study of Cataract

Sponsor
Eye & ENT Hospital of Fudan University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05682001
Collaborator
National Natural Science Foundation of China (Other)
150
1
47.9
3.1

Study Details

Study Description

Brief Summary

To study the molecular pathogenesis of cataract and explore possible treatments,anterior lens capsules were collected from cataract patients

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Anterior lens capsules were collected from the patients with DC and ARC, and transparent crystals of cadaveric eyes. M6A epitranscriptomic microarray was performed to investigate the altered m6A modifications and determine the differentially expressed mRNAs. The potential role of dysregulated m6A modification levels was predicted through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Real-time polymerase chain reaction was performed to identify the dysregulated expression of RNA methyltransferases, demethylases, and readers.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    150 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    The Molecular Pathogenesis Study of Cataract
    Actual Study Start Date :
    Jan 1, 2022
    Anticipated Primary Completion Date :
    Dec 1, 2023
    Anticipated Study Completion Date :
    Dec 30, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    DC group

    Anterior lens capsule tissues from DC patients

    ARC group

    Anterior lens capsule tissues from ARC patients

    NC group

    anterior lens capsules collected from three age-matched transparent crystals of cadaveric eyes

    Outcome Measures

    Primary Outcome Measures

    1. m6A modification of mRNAs [1 month]

      Epitranscriptomic microarray analysis reveals the differential m6A modification of mRNAs in DC samples

    2. expression level of mRNAs [1 month]

      the m6A microarray analyses provide data for mRNA expression levels

    3. levels of methylated mRNA [1 month]

      in vitro validation of the diverse expression levels of methylated mRNA

    4. levels of RNA methyltransferase [1 month]

      in vitro validation of the diverse expression levels of RNA methyltransferase

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • diabetic cataract

    • underwent cataract surgery

    Exclusion Criteria:
    • Combined with other eye diseases

    • underwent other eye surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Eye & ENT Hospital of Fudan University Shanghai Shanghai China 200031

    Sponsors and Collaborators

    • Eye & ENT Hospital of Fudan University
    • National Natural Science Foundation of China

    Investigators

    • Principal Investigator: Jin Yang, PhD, Eye & ENT Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jin Yang, Professor, Eye & ENT Hospital of Fudan University
    ClinicalTrials.gov Identifier:
    NCT05682001
    Other Study ID Numbers:
    • CMP
    First Posted:
    Jan 12, 2023
    Last Update Posted:
    Jan 12, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 12, 2023